In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Chimerix (CMRX – Research Report), with a price target of $11.00. The company’s shares closed yesterday at $2.36.
White covers the Healthcare sector, focusing on stocks such as Clovis Oncology, Karyopharm Therapeutics, and TG Therapeutics. According to TipRanks, White has an average return of -15.5% and a 32.42% success rate on recommended stocks.
Chimerix has an analyst consensus of Strong Buy, with a price target consensus of $8.00.
The company has a one-year high of $7.42 and a one-year low of $1.27. Currently, Chimerix has an average volume of 6.32M.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CMRX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.
Read More on CMRX:
- H.C. Wainwright Keeps Their Buy Rating on Marathon Digital Holdings (MARA)
- What’s Next For SoftBank Stock After Record Q1 Loss
- So-Young to Report Second Quarter 2022 Financial Results on August 16, 2022
- Spirit Airlines Reports Second Quarter 2022 Results
- RadNet Reports Second Quarter Financial Results and Reaffirms 2022 Financial Guidance Ranges